


Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in front line metastatic triple negative breast cancer triggers macrophage reprogramming, immune activation and extracellular maxtrix reorganization in the tumor microenvironment

PD-L1 Agnostic



Authors: Brenda C O'Connell, Charley Hubbard, Nora Zizlsperger, Donna Fitzgerald, Jeffrey L Kuotk, Judith A Varner, Robert Ilaria, Jr., Melody A Cobleigh, Dejan Juric, Kate HR Tkaczuk, Anthony Elias, Arielle Lee, Shaker Dahkil, Erika Hamilton, Hatem Soliman, Stephane Peluso.

Correspondence
brendaoconnell5@gmail.com

PD-L1 Negative



In Brief
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy reprograms macrophages and activates an anti-tumor immune response regardless of PD-L1 status and reduces expression of genes involved in extracellular matrix reorganization and fibrosis in PD-L1 negative tumors that are rich in ECM proteins